Metastatic hormone-sensitive prostate cancer
Emily MenendezmHSPC | September 13, 2023
The PNI is commonly used as a prognostic factor for malignant tumors, but its potential use for prostate cancer is unknown.
Read More
Emily MenendezmHSPC | August 11, 2023
Patients with a suboptimal PSA response who are administered intensified ADT often experience worse survival outcomes.
Emily MenendezProstate Cancer | August 2, 2023
A meta-analysis sought to determine the efficacy of systemic therapies in patients with PCa and poor performance status.
Emily MenendezProstate Cancer | June 20, 2023
The updated guideline emphasizes the use of PSMA PET for periodic staging, as well as the use of ADT.
Emily MenendezASCO 2023 | June 3, 2023
Results from the CHAARTED trial demonstrated that ADT and docetaxel improves OS and QOL at 12 months compared with ADT alone.
Emily MenendezmHSPC | May 18, 2023
Researchers studied several trials including LATITUDE and STAMPEDE to find similar characteristics among ARAT treatments.
Emily MenendezAUA 2023 | April 28, 2023
The STAMPEDE trial examined the addition of zoledronic acid, docetaxel, or both to ADT for the treatment of mHSPC.
Leah LawrenceProstate Cancer | April 19, 2023
Several physicians highlight the newest data on radiation for metastatic prostate cancer and its role moving forward.
Emily MenendezmHSPC | April 14, 2023
New research has reported updates on the primary OS analysis of the ENZAMET trial to define the benefit of enzalutamide.
Emily MenendezExpert Interviews | March 30, 2023
A recent study examined safety and efficacy from the ARASENS trial for certain subgroups by disease volume and risk.
David Ambinder, MDmHSPC | February 23, 2023
Is it possible to avoid or delay systemic therapy for patients with oligometastatic prostate cancer? A new study suggests so.
Zachary BessetteASCO GU Symposium 2023 | February 16, 2023
An analysis highlighted real-world treatment of patients with mHSPC in the community who received at least 1 line of therapy.
Tanya Dorff, MDmHSPC | February 13, 2023
Tanya Dorff, MD, shares the barriers to utilizing PARP inhibitors plus AR-targeted agents in early prostate cancer settings.
Matthew Deek, MDmHSPC | January 31, 2023
Dr. Deek shares what research should be done to better personalize care for patients with oligometastatic prostate cancer.
Matthew Deek, MDmHSPC | January 31, 2023
Dr. Deek shares what “high-risk mutation” signified in his study and how patients with “high-risk mutation” should be ...
Matthew Deek, MDNext-Generation Imaging | January 31, 2023
Dr. Deek shares how PSMA imaging used in both the STOMP and ORIOLE trials.
Matthew Deek, MDmHSPC | January 31, 2023
Dr. Deek shares how he evaluated long-term outcomes of MDT in om CSPC in both the ORIOLE and STOMP trials.
Emily MenendezRLT-PSMA | January 12, 2023
While PSMA-RLT is typically used during later disease stages, patients in earlier disease stages may benefit as well.
Emily MenendezmCRPC | January 4, 2023
Liquid biopsy of CTCs may serve as an effective prediction biomarker for docetaxel response in patients with CRPC and mHSPC.
Zachary BessettemHSPC | December 7, 2022
High testosterone levels measured by a liquid chromatography-tandem mass spectrometry assay may predict castration response.